Quarterly report pursuant to Section 13 or 15(d)

Licensing Arrangements (Details)

v3.20.2
Licensing Arrangements (Details) - Licensing agreements for development and commercialization - USD ($)
$ in Millions
1 Months Ended 6 Months Ended
Jul. 31, 2018
Jun. 30, 2018
Jun. 30, 2020
Aug. 07, 2020
Pharmbio Korea Inc        
Licensing Arrangements        
Upfront payment   $ 3.0    
Withholding taxes   0.5    
Commercialization milestone payments   $ 0.5    
Time period for written notice to terminate license agreement   180 days    
Pharmbio Korea Inc | Minimum        
Licensing Arrangements        
Time period to form a committee prior to the anticipated date of regulatory approval     6 months  
Pharmbio Korea Inc | Maximum        
Licensing Arrangements        
Royalties on product sales, percentage   20.00%    
Jiangsu Nhwa Pharmaceutical Co Ltd        
Licensing Arrangements        
Upfront payment $ 2.5      
Withholding taxes $ 0.3      
Time period for written notice to terminate license agreement     180 days  
Milestone payment upon regulatory approval in China     $ 3.0  
Milestone payment upon sales targets reached in China     $ 6.0  
Royalty percentage on net product sales in China after milestones met     10.00%  
Jiangsu Nhwa Pharmaceutical Co Ltd | Minimum        
Licensing Arrangements        
Time period to form a committee prior to the anticipated date of regulatory approval     6 months  
Subsequent event        
Licensing Arrangements        
Milestone payment upon regulatory approval in China       $ 3.0
Subsequent event | Jiangsu Nhwa Pharmaceutical Co Ltd        
Licensing Arrangements        
Milestone payment upon regulatory approval       $ 3.0